About SINOMAB BIO-B Company

China Antibody Pharmaceutical Co., Ltd. (“China Antibody” or the “Company”, stock code: 3681.HK) focuses on the research, development, manufacture and commercialization of immune-mediated disease therapies. The company focuses on scientific research and development. Its flagship product, SM03, is the world's first potential anti-CD22 monoclonal antibody used to treat rheumatoid arthritis. It has already entered phase III clinical trials for rheumatoid arthritis in China, and has been included in the country's 13th Five-Year New Drug Creation Project. In addition, there are a number of first-in-target (first-in-target) and first-in-class (first-in-class) drugs that are potentially under development. Some are already in the clinical stage. Indications cover diseases such as rheumatoid arthritis, systemic lupus erythematosus, non-Hodgkin's lymphoma, and asthma that do not meet clinical needs.